Researchers used mice studies to reveal that the activity of an enzyme called MAO (yellow) is directly correlated with the progression of Alzheimer's disease and may be used to stage the disease
Alzheimer's disease affects more than 35 million people, a number that is expected to increase in the coming years. Currently, Alzheimer's diagnoses rely on clinical neuropathologic assessment of amyloid-β (Aβ) peptide aggregates (plaques) and neurofibrillary tangles. But in ACS Central Science, researchers reveal that an enzyme already implicated in a host of neural disorders could someday serve as a biomarker.
